YM155 (Sepantronium Bromide)

Catalog No.S1130

YM155 (Sepantronium Bromide) Chemical Structure

Molecular Weight(MW): 443.29

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 45 Publications

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 NEjwcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;BO|IhcA>? M37Ib2ROW09? M2ra[mlEPTB;MD6wNFkhyrFiMD6wNFA6KM7:TR?= NHzRPYczPTZ3OUezNS=>
M-07e NXy1RWpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHNflg5PzJiaB?= M1f0SWROW09? MorRTWM2OD1yLkC0NEDDuSByLkCxN{DPxE1? NGTMcZIzPTZ3OUezNS=>
THP-1 NHXPRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPiTll2PzJiaB?= Mn3tSG1UVw>? M3PBN2lEPTB;MD6wOVEhyrFiMD6wNVMh|ryP NH2xZWgzPTZ3OUezNS=>
CMK MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPnO|IhcA>? MY\EUXNQ M{K5eWlEPTB;MD6wOVMhyrFiMD6wNFkh|ryP M1PRPFI2PjV7N{Ox
MV4-11 NWPie41vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS4W5A4OiCq M{O3XGROW09? NFHRRo1KSzVyPUCuNFU2KMLzIECuNFI5KM7:TR?= M1TXclI2PjV7N{Ox
AML-193 M2TLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUm3NkBp NG[4NlhFVVOR Moi1TWM2OD1yLkS2NkDDuSByLkC2NEDPxE1? NHPVXmUzPTZ3OUezNS=>
HL-60 NH\tVXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fpcVczKGh? NUTwZot2TE2VTx?= NYP5OYRvUUN3ME2wMlAxOSEEsTCwMlAxODJizszN NEDqd4IzPTZ3OUezNS=>
ML-2 Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:xUFczKGh? M4jkWWROW09? M4f1OmlEPTB;MD6wNFkhyrFiMD6wNFIh|ryP MWKyOVY2QTd|MR?=
OCI/AML3 M{foXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HhVVczKGh? NHi0NoRFVVOR MWTJR|UxRTBwMEGxJOKyKDBwMECyJO69VQ>? MYiyOVY2QTd|MR?=
HEL M3LBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfCeZBZPzJiaB?= MUfEUXNQ MVPJR|UxRTBwNUW5JOKyKDBwMEO4JO69VQ>? MnPhNlU3PTl5M{G=
ME-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7NWIt5PzJiaB?= NWLEVmdSTE2VTx?= M4X3b2lEPTB;MD62PFQhyrFiMD6xO|kh|ryP MljZNlU3PTl5M{G=
THP-1 NHvnO4xCeG:ydH;zbZMhSXO|YYm= NXjwW|VxOcLizszN MYS3NkBp NGXpZodFVVOR M2DrPIlv\HWlZYOgZZBweHSxc3nz M3[0WFI2PjV7N{Ox
M-07e NEfyOIpHfW6ldHnvckBCe3OjeR?= NHP4N2Ex6oDVMdMg{txO NV24ZZpnPzJiaB?= MY\EUXNQ MWrpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw MYGyOVY2QTd|MR?=
THP-1 Mke1SpVv[3Srb36gRZN{[Xl? M1fv[FDjiJNzwrFOwG0> NV74OWFHPzJiaB?= M2XLc2ROW09? M1i3RYlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= MVOyOVY2QTd|MR?=
CMK M4HhNmZ2dmO2aX;uJGF{e2G7 MnrONQKBmzIEoN88US=> M2P2dFczKGh? Ml2ySG1UVw>? MYTpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw NUO5bHRuOjV4NUm3N|E>
AML-193 NHLwd3dHfW6ldHnvckBCe3OjeR?= MkjpNQKBmzIEoN88US=> NYO0U5JzPzJiaB?= M1n5WGROW09? MojGbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= NXTrbmg5OjV4NUm3N|E>
Kasumi-1 NX\LVHAzTnWwY4Tpc44hSXO|YYm= M1nOXVDjiJNzwrFOwG0> MVK3NkBp MVLEUXNQ NXHHblN4cW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> MkHSNlU3PTl5M{G=
MV4-11 MWTGeY5kfGmxbjDBd5NigQ>? MVSw5qCUOcLizszN NEfsNW44OiCq Mnv3SG1UVw>? NWDUOndvcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> MXWyOVY2QTd|MR?=
MUG-Chor  M{O5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LvXFAuPSEQvF2= MXqyOE81QCCq NX[xWVNPUUN3ME23MlA26oDLbl2g[o9zKDR6aB?= NWDJXYRFOjV4NECxPFU>
U-CH1  MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTReVgxNTVizszN M1XnTVI1NzR6IHi= Ml;jTWM2OD17LkCz5qCKdk1iZn;yJFQ5cA>? NFr4U3gzPTZ2MEG4OS=>
KATOIII NEKyZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LDW|ExNzJyIH7N NXLwTI9RPDhiaB?= NHzGWJVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXOwZlB1OjV4M{WwOVU>
AGS  MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ryNVExNzJyIH7N NID1VZc1QCCq MVfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MU[yOVY{PTB3NR?=
SACC-83 NYTieI0yTnWwY4Tpc44hSXO|YYm= MlO4OUBvVQ>? MmPlOFghcA>? M{DZc4Rm[3KnYYPld{BvfWOuZXHyJIV5eHKnc4Ppc44hd2ZiSFnGMVHPuQ>? NWPiXlNHOjV2OEW2N|U>
INA-6 NH;qXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHiOY94OC13MECgcm0> NWi0O2RPPDhiaB?= MWrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmnONlUzQTZ7N{i=
U-266 NIPofZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTFNE02ODBibl2= M2jDU|Q5KGh? M2raWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFXqboozPTJ7Nkm3PC=>
MOLP-8 MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj1bZAxNTVyMDDuUS=> M325UFQ5KGh? NEDPc5hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWSyOVI6Pjl5OB?=
HG-1 NIfOS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTGOWUxNTVyMDDuUS=> NYLQTIZWPDhiaB?= MVvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mn\ZNlUzQTZ7N{i=
NCI-H929 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\4T5R{OC13MECgcm0> M3PqblQ5KGh? NULTOHZIcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NInqVYQzPTJ7Nkm3PC=>
OPM-2 M2fyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqwMVUxOCCwTR?= MVK0PEBp MYHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NUnVeVJNOjV{OU[5O|g>
L-363 NVTre|lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TRWFAuPTByIH7N MV20PEBp NVrTNWI4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MoDRNlUzQTZ7N{i=
MOLP-2 M{LmT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vGcVAuPTByIH7N NFXUUG01QCCq M1:3colvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1XBcFI2Ojl4OUe4
KMS-12-BM M3r5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fR[lAuPTByIH7N M1PDNFQ5KGh? MWLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NWL2SZh2OjV{OU[5O|g>
SK-MM-2 M3TxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[wV49OOC13MECgcm0> NYi4ZoJVPDhiaB?= NWPNUYlOcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFvQTpkzPTJ7Nkm3PC=>
U-266 MVnBdI9xfG:|aYOgRZN{[Xl? NFm2[lMxNTVyIH7N MUGyOEBp MULpcoR2[2W|IHHwc5B1d3Orcx?= NVnxTlV4OjV{OU[5O|g>
INA-6  NF7CcZFCeG:ydH;zbZMhSXO|YYm= M3npc|AuPTBibl2= NWnZbItIOjRiaB?= M{fST4lv\HWlZYOgZZBweHSxc3nz MlW4NlUzQTZ7N{i=
MCF7 MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknqO|IhcA>? MX\JR|UxRTF|INMxJFYhdk1? MUWyOVIzODJ{NR?=
MCF7-TamR6 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWq3NkBp NHHiNWZKSzVyPUigxtEhPiCwTR?= M{LZWlI2OjJyMkK1
MCF7-TamR7 NGfZbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYq3NkBp NGPaTWdKSzVyPUigxtEhOyCwTR?= NXH5[2I4OjV{MkCyNlU>
MCF7-TamR8 MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXS3NkBp MX7JR|UxRTF3INMxJFYhdk1? NVzofmt5OjV{MkCyNlU>
MCF7-TamC3 NXPvWJRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXLZnU4OiCq M3PWWGlEPTB;NjFCtUA{KG6P MnXNNlUzOjB{MkW=
MCF7-TamC6 NUDKO2hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;EXFk4OiCq MlPUTWM2OD14INMxJFAvOSCwTR?= MkLRNlUzOjB{MkW=
MDA-MB-231 M{\RR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjQfnc4OiCq NVvIbWE4UUN3ME21JOKyKDFibl2= MkG4NlUzOjB{MkW=
SK-BR-3 NIG3bGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy5UHo4OiCq MnLhTWM2OD15INMxJFAvOyCwTR?= Mnz5NlUzOjB{MkW=
Eca109 NWTMbZZsTnWwY4Tpc44hSXO|YYm= NGHUWHEyNTVyIH7N M37jS|Q5KGh? NYnjeodlTE2VTx?= NU[5cm86e3WycILld5NmeyC|dYL2bZZqdiCneIDy[ZN{cW:wIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M1P6RVI2OTN7M{m1
TE13 NG[xOmFHfW6ldHnvckBCe3OjeR?= NYHDVVRiOS13MDDuUS=> NX7BS5F1PDhiaB?= NXrPS3cyTE2VTx?= M2PnS5N2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NEP3ToEzPTF|OUO5OS=>
Eca109 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVGwMVExOCCwTR?= M3vMTVI1NzR6IHi= MoHXSG1UVw>? MlzD[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYSyOVE{QTN7NR?=
TE13 NXLHNW9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDBNE0yODBibl2= MYKyOE81QCCq M3rqb2ROW09? MUPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWiyOVE{QTN7NR?=
MT-3 MXvLbY5ie2ViQYPzZZk> M{LBd|czKGh? NGm0XG5FVVOR MXrJR|UxRTJwOE[gxtEhOC53NDDuUUBnd3JiRGK0JIV5eHKnc4Ppc44> M2TzfFI1QDZ4NUi1
MDA-MB-468 MnzPT4lv[XOnIFHzd4F6 M37MWlczKGh? MXrEUXNQ M175WmlEPTB;MD6xNUDDuSByLkCxJI5OKG[xcjDEVlQh\XiycnXzd4lwdg>? NIL0bYkzPDh4NkW4OS=>
SUM-159 NIXUcFFMcW6jc3WgRZN{[Xl? NF65W|A4OiCq MlvFSG1UVw>? NVmyOmkyUUN3ME2xMlczKMLzIECuN|Mhdk1iZn;yJGRTPCCneIDy[ZN{cW:w NXXjUXVtOjR6Nk[1PFU>
MT-3 MXTLbY5ie2ViQYPzZZk> MUi3NkBp M4XNXGROW09? NWDkeWtGUUN3ME21OE4yOSEEsTC0MlMzKG6PIH\vdkBFWjViZYjwdoV{e2mxbh?= NHr6PYozPDh4NkW4OS=>
MDA-MB-468 MkHVT4lv[XOnIFHzd4F6 MnrkO|IhcA>? MVfEUXNQ NGrLfpFKSzVyPUCuNFchyrFiMD6wNkBvVSCob4KgSHI2KGW6cILld5Nqd25? MmS0NlQ5PjZ3OEW=
SUM-159 MXLLbY5ie2ViQYPzZZk> NGPPSpc4OiCq NXHQRlhQTE2VTx?= MlXRTWM2OD14OT60JOKyKDRwMkOgcm0h\m:{IFTSOUBmgHC{ZYPzbY9v MV:yOFg3PjV6NR?=
MT-3 + NAC MorpT4lv[XOnIFHzd4F6 M1jpV|czKGh? Mo\qSG1UVw>? M1fZTWlEPTB;NU[uNkDDuSB{LkC3JI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? NXjudXdMOjR6Nk[1PFU>
MT-3 + SB203580 MmDaT4lv[XOnIFHzd4F6 MlHrO|IhcA>? NV\NeG5TTE2VTx?= M1jPOmlEPTB;M{iuOFEhyrFiNT6wNkBvVSCob4KgSHI2KGW6cILld5Nqd25? M4LINlI1QDZ4NUi1
DB NWmxZ4Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PXdVExKG6P MUeyOEBp Mnm5SG1UVw>? MYnpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= MXSyOFQ5PjV7NR?=
SU-DHL-8 NVnmdGEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;CNVAhdk1? MnLZNlQhcA>? MXjEUXNQ NG\xOZNqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> M1fhd|I1PDh4NUm1
WSU-DLCL2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHBbnBGOTBibl2= M3zaSFI1KGh? MmfUSG1UVw>? MV\pcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= M2rtV|I1PDh4NUm1
ACC-2 MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3GyflAuOTByIH7N NWTZWINkOjRiaB?= M1LRNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmjQNlQ{PzB7OUW=
ACC-2 NF;JdYtCeG:ydH;zbZMhSXO|YYm= NUTTO2ZVOC1{MDDuUS=> Mk\5NlQhcA>? Mk\GbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mmj0NlQ{PzB7OUW=
ACC-2 NELLfmFHfW6ldHnvckBCe3OjeR?= MkDiNE0zOCCwTR?= MUWyOEBp M{L1Oolv[3KnYYPld{B1cGViY3;ueoVze2mxbjDv[kBNSzOLIITvJGxEO0mL MYiyOFM4ODl7NR?=
BFTC905 Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqwMVExODBibl2= NGH5[VE1QCCqwrC= NXvIbFJ4TE2VTx?= NI\hN3RKSzVyPUKwJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUeyOFI6PzZ2NB?=
T24 M3Owdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G2e|AuOTByMDDuUS=> MV60PEBpyqB? MoDPSG1UVw>? M1fsOGlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{C2b|I1Ojl5NkS0
TSGH8301  M33GWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jJfFAuOTByMDDuUS=> MWm0PEBpyqB? NV7FXWNQTE2VTx?= M3rtUWlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NV;MZol[OjR{OUe2OFQ>
BFTC909 M1H5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXoNE0yODByIH7N NXeyNIdoPDhiaNMg NXHmfZY4TE2VTx?= MlvSTWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXS3d|I5OjR{OUe2OFQ>
BFTC905 MXjBdI9xfG:|aYOgRZN{[Xl? NVz1ZZF5OjBibl2= NYXG[npjPDhiaB?= NGTVT3JFVVOR MXPpcoR2[2W|IHHwc5B1d3Orcx?= MVGyOFI6PzZ2NB?=
BFTC905 NE\kZoJHfW6ldHnvckBCe3OjeR?= MoDmNlAhdk1? M1THbVQ5KGh? Mk[4SG1UVw>? NIrafFZl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVEN|Qj3JTS=> NVvUeJo2OjR{OUe2OFQ>
A2780p M2L3XmZ2dmO2aX;uJGF{e2G7 MVuwMVExOCCwTR?= NVq4TlQ5OjRiaB?= M2PFXGROW09? NXHFRlVLcW6mdXPld{BUfXK4aY\pckBld3ewcnXneYxifGmxbtMg M3T3VFI1OjZ{OEe1
A2780cis Ml7uSpVv[3Srb36gRZN{[Xl? M1L3flAuOTByIH7N M{\oelI1KGh? NXGwflRzTE2VTx?= MYXpcoR2[2W|IGP1dpZqfmmwIHTve45z\We3bHH0bY9vyqB? NIXjT44zPDJ4Mki3OS=>
A2780p MmG5RZBweHSxc3nzJGF{e2G7 MmGyOU0yODBibl2= Ml:4NlQwPDhiaB?= NEPhcItFVVOR MX;pcoNz\WG|ZYOgZZBweHSxc3nzJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy NWXlcHJtOjR{NkK4O|U>
A2780cis MmL6RZBweHSxc3nzJGF{e2G7 M1PHZVUuOTByIH7N M2C0VVI1NzR6IHi= MmTUSG1UVw>? MVfpcoNz\WG|ZYOgZZBweHSxc3nzJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy M1m2T|I1OjZ{OEe1
SH-SY5Y M2P5fGFxd3C2b4Ppd{BCe3OjeR?= MW[xM|ExNzFyMDFCuW0> Mom4O|IhcA>? NHTQbW5FVVOR MVPpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MlfqNlQzPTR3NkC=
HL-60 NV3mfXJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PGe|czyqCq MmX6SG1UVw>? MUPJR|UxRTBwMzDuUS=> MnLLNlM3OTh6NkK=
U937  NHW2[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTWO|LDqGh? M1\EN2ROW09? NFLDN|dKSzVyPUCuPEBvVQ>? MXiyN|YyQDh4Mh?=
HL-60  NETJVXpHfW6ldHnvckBCe3OjeR?= MkKzNeKh|ryP MkP0Ok8yOi9{NDDo M1:0c2ROW09? Mn;6bY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gd5Vzfmm4aX6= MUKyN|YyQDh4Mh?=
U937  MULGeY5kfGmxbjDBd5NigQ>? NUHSe|d[OcLizszN MWK2M|EzNzJ2IHi= M3v3[mROW09? MVLpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDzeZJ3cX[rbh?= NFTUbFAzOzZzOEi2Ni=>
HL-60 MUfBdI9xfG:|aYOgRZN{[Xl? MkTsNE4yNzFizszN NEHBbJc5KGh? MUPEUXNQ M2TJUYlv\HWlZYOgZZBweHSxc3nz MnPYNlM3OTh6NkK=
Sk-NEP-1  NV7mb4ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKxMVExODByIH7N MUKyOEBp NVP6SYlbTE2VTx?= M3HQWGlEPTB;MUCwJI5O MWOyN|I3PzZ7OR?=
SK-NEP-1  MY\BdI9xfG:|aYOgRZN{[Xl? MlzMOVAwOTByIH7N MV6xNk8zPCCq Mmq5SG1UVw>? MmCybY5lfWOnczDhdI9xfG:|aYO= MlvpNlMzPjd4OUm=
TC-32 M4LSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInzNWsxNjFvMUCwNEBvVQ>? NIm5fIdGSzVyPUOuNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M1\HN|IzQTZzN{[z
TC-71 MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHNNE4yNTFyMECgcm0> M3L6dWVEPTB;NT63JI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUD2PWR3OjJ7NkG3OlM>
SK-ES-1 NYOwTYp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHkNE4yNTFyMECgcm0> M1Pzc2VEPTB;Mj64JI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NE\xdlkzOjl4MUe2Ny=>
RD-ES MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCwMlEuOTByMDDuUS=> MXrFR|UxRTZwMjDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmnkNlI6PjF5NkO=
HEK293 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHSNE4yNTFyMECgcm0> MXPFR|UxRTJ|LkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYrkRoFXOjJ7NkG3OlM>
M059J MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jHPFAuPTBibl2= NV;2Z4s3PDhiaB?= NFzMUYhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYOyNlc4ODFzMB?=
M059K NIr1TldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLCNE02OCCwTR?= NV7oUmNFPDhiaB?= M4LnTolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVfl[JdKOjJ5N{CxNVA>
M059J NF7aVWVCeG:ydH;zbZMhSXO|YYm= NVvSd5NoOzBibl2= M3jmOFI1KGh? NHriNI5qdmS3Y3XzJIFxd3C2b4Ppdy=> MknZNlI4PzBzMUC=
M059K NEfsNVhCeG:ydH;zbZMhSXO|YYm= M2DMRVMxKG6P Mn;kNlQhcA>? MkHJbY5lfWOnczDhdI9xfG:|aYO= M1XYN|IzPzdyMUGw
PANC-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLNT|d2OC5yMT2xNFAxKG6P NH\6fIQ1QCCq M4rpcWlEPTB;Mz62PUBvVQ>? NFmzWlQzOjd{M{i3NS=>
MIAPaCa-2 NUn3V3FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYewMlAyNTFyMECgcm0> Mn6xOFghcA>? MXPJR|UxRTJ7LkO2JI5O MlfINlI4OjN6N{G=
BxPC-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nrT|AvODFvMUCwNEBvVQ>? NYXPUWV2PDhiaB?= Mm\YTWM2OD1|MD6yOkBvVQ>? NX3xUo82OjJ5MkO4O|E>
PANC-1 M3WyWmZ2dmO2aX;uJGF{e2G7 M1TXeVAuOTByMDDuUS=> NWDabXZ5OjRiaB?= NELCTYpqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> MWOyNlczOzh5MR?=
MIAPaCa-2 MYLGeY5kfGmxbjDBd5NigQ>? NH:2emUxNTFyMECgcm0> NIO4TnczPCCq M{HR[Ilv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gXGlCWCCjbnSgd5Vzfmm4aX6g[ZhxemW|c3nvci=> Ml2yNlI4OjN6N{G=
BxPC-3 MojXSpVv[3Srb36gRZN{[Xl? M3rMPVAuOTByMDDuUS=> M4jXTFI1KGh? NF3WXFFqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> M3jpd|IzPzJ|OEex
RPMI-7951 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;yVWdKPTB;Mz6yJI5O M4LTbFIyPzN5NUCy
SK-MEL-5 M4D1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPHTVUxRTRwMjDuUS=> MUiyNVc{PzVyMh?=
A375 M1;lVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLHTVUxRTZwMzDuUS=> NVXxR4NtOjF5M{e1NFI>
SK-MEL-28 NUTvb41OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\HTVUxRTdwNjDuUS=> MX6yNVc{PzVyMh?=
SK-MEL-2 NEDUe3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjaN3pXT0l3ME2xNUBvVQ>? NGHlPWkzOTd|N{WwNi=>
DB M3nGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLqOFjDqGh? NFrzUW1IUTVyPUOuOUBvVQ>? MoXQNlEzOzd3MEi=
Pfeiffer M{jTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i3b|Q5yqCq NVyyTW5kT0l3ME2zMlkhdk1? MkWxNlEzOzd3MEi=
SU-DHL-5 NIjIXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVS0POKhcA>? M4\id2dKPTB;MD6yN{BvVQ>? NGXPO4IzOTJ|N{WwPC=>
SU-DHL-8 NUizNHhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnhN3M1QMLiaB?= NIfTfIhIUTVyPUGuOEBvVQ>? M{TqR|IyOjN5NUC4
WSU-DLCL-2 NGfufFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUm0POKhcA>? NE\vR41IUTVyPUGuOEBvVQ>? Mnr4NlEzOzd3MEi=

... Click to View More Cell Line Experimental Data

In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

+ Expand
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Formulation: Dissolved and diluted in saline immediately before administration
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol 6 mg/mL (13.53 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01100931 Completed NSCLC|Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 2010 Phase 1|Phase 2
NCT01100931 Completed NSCLC|Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 2010 Phase 1|Phase 2
NCT01038804 Completed Breast Cancer Astellas Pharma Inc December 2009 Phase 2
NCT01038804 Completed Breast Cancer Astellas Pharma Inc December 2009 Phase 2
NCT01023386 Completed Cancer Astellas Pharma Inc November 2009 Phase 1
NCT01009775 Completed Melanoma Astellas Pharma Inc November 2009 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Survivin Signaling Pathway Map

Related Survivin Products0

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID